Corline Biomedical (CLBIO) Q1 2026 earnings summary

Executive summary

• Achieved record quarterly revenue from commercial product and reagent sales in Q1 2026, with nearly 90% of revenue from these sources.

• Strategic focus on expanding partnerships, especially with Kardium, and strengthening presence in the US market.

• Ongoing efforts to secure partnerships for Renaparin® and further develop the CHSTM Growth Initiative.

Financial highlights

• Net sales reached 4,291 KSEK, up from 2,055 KSEK year-over-year and higher than Q4 2025.

• Result after financial items improved to -2,501 KSEK from -3,071 KSEK year-over-year.

• Earnings per share were -0.10 SEK, compared to -0.13 SEK in Q1 2025.

• Cash and cash equivalents at period end were 32,902 KSEK, up from 11,735 KSEK year-over-year.

• Equity at period end was 102,948 KSEK, with an equity ratio of 86.9%.

Outlook and guidance

• Expectation that product and reagent sales will continue to dominate revenue mix, improving margins.

• Anticipate further growth driven by expanded US market presence and strengthened partnerships.